Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

NCT06901622 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Interventions

DRUG: Camrelizumab, anlotinib, nab-paclitaxel, S-1
DRUG: Camrelizumab, nab-paclitaxel, S-1

Sponsor

The First Affiliated Hospital of Zhengzhou University